Celgene Gets a JAK2 for $1.1B, Novo Bids for Ablynx & Pfizer Drops Neuro: Pre#JPM18 Wrap

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.